The prolonged treatment with imatinib lead to decrease of MIC-A/B on GIST and an increase of NKp46+ NK cells infiltration into tumor core associating with a reduced relapse [93]. This evidence concerns the gene NCR1 and gastrointestinal stromal tumor.